Loading...
NPI 1144606542 · Troy, MI · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Rhb Laboratories Inc is a clinical medical laboratory provider located in Troy, Michigan. This profile covers 10 Medicare and 42 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Rhb Laboratories Inc |
| Address | 575 E Maple Rd |
| City | Troy |
| State | MI |
| ZIP | 48083 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 7, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $25.3M |
| Medicare | $2.9M |
RHB LABORATORIES INC is effectively Medicaid‑focused: the provider reports $25.3M in lifetime Medicaid revenue versus $2.9M in Medicare revenue, indicating Medicaid is the primary payer by scale for this entity. This payer mix suggests the lab’s commercial strategy and operational footprint are concentrated on state Medicaid business and high-volume public health testing contracts.
Medicare revenue is highly concentrated: the precomputed top‑3 Medicare codes account for 86.6% of the provider’s Medicare revenue, led by G0483, G0482, and 87637. That mix indicates a Medicare portfolio dominated by definitive drug testing codes (G0483/G0482) with a smaller but material component of multiplex respiratory viral testing (87637).
G0483 is the single largest Medicare driver: it produced $1.6M in Medicare revenue (56.5% of the provider’s Medicare total) and the provider ranks #13 of 1063 nationally (99th percentile; notably above typical national volume). This ranking establishes RHB LABORATORIES as a major national-volume performer specifically for high‑complexity, multi‑class definitive drug testing.
At the state level for Medicaid, RHB is a dominant high‑volume COVID and respiratory testing provider: U0003 generated $7.8M (30.9% of Medicaid revenue) with 130.1K claims and ranks #2 of 157 in‑state (99th percentile; extreme outlier, far above typical state volume). In addition, U0005 is listed as $2.2M (8.8% of Medicaid revenue) and ranks #1 of 134 in‑state (100th percentile; extreme outlier), together signaling very large high‑throughput SARS‑CoV‑2 testing capacity.
Beyond COVID testing, the provider’s Medicaid mix also shows significant volumes in definitive drug testing: G0483 and G0482 together account for a substantial share of Medicaid billing ($5.8M and $3.1M respectively) and rank in high state percentiles (G0483 #4 of 62, 95th percentile; G0482 #3 of 67, 97th percentile). This pattern supports a dual service line profile — large‑scale infectious disease molecular testing plus comprehensive definitive drug panel testing — consistent with a centralized laboratory that handles both high‑complexity toxicology and high‑throughput molecular assays.
Operational indicators point to a high‑throughput centralized laboratory model: Medicaid claim counts such as 130.1K claims for U0003 and 46.1K claims for G0483 (and similarly large counts for G0482 and 87637) align with processing volumes expected from labs that use high‑throughput technologies and specimen routing at scale. The presence of both high claim volumes and codes explicitly tied to high‑throughput methods (U0003/U0005) corroborates substantial lab processing capacity and throughput orientation.
Revenue concentration across payers creates business sensitivity to coding and policy changes: top‑3 Medicare codes make up 86.6% of Medicare revenue and the top‑3 Medicaid codes make up 66.0% of Medicaid revenue, so shifts in reimbursement, coverage, or utilization for G0483/G0482 or U0003/related COVID codes would have outsized impact on total program revenues. For payers and network managers, these concentrations flag the provider as specialized and potentially vulnerable to targeted policy changes for those high‑share codes.
The provider has an established presence with its NPI enumerated on 2015-08-07 (~11 years ago), indicating a multi‑year operational history during which it scaled to high volumes on both Medicaid and Medicare lines. Coupled with the high percentile rankings on several codes, this tenure suggests sustained growth into a prominent state‑level COVID testing and national high‑complexity drug testing participant.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6,660 | $240 | $1.6M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,450 | $200 | $672K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 1,340 | $140 | $187.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,800 | $60 | $109.9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 630 | $110 | $70.4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 450 | $150 | $68.8K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 370 | $140 | $51.4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 570 | $70 | $42.3K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 520 | $50 | $25.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 570 | $30 | $14.3K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
42 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 130,110 | $60 | $7.8M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 46,110 | $130 | $5.8M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 32,460 | $100 | $3.1M |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 22,930 | $110 | $2.5M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 117,460 | $20 | $2.2M |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 13,890 | $110 | $1.5M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12,430 | $70 | $907.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 21,300 | $40 | $745.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7,690 | $70 | $569.1K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 4,070 | $40 | $154.5K |
Showing 1–10 of 42
How this provider's Medicaid billing volume and revenue compare to other Michigan providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Michigan median
42 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 60 | 1,310 | $130 | $1.1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 70 | 680 | $100 | $604K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2 | 160 | 2,720 | $60 | $546.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 8 | 50 | 650 | $80 | $298.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 3 | 130 | 1,180 | $80 | $231.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 16 | 150 | 2,250 | $30 | $202.4K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 4 | 140 | 290 | $80 | $161.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 19 | 240 | 2,430 | $20 | $152.2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1 | 130 | 2,270 | $20 | $140.4K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 42 | 410 | 350 | $30 | $50.2K |
Showing 1–10 of 42
Other providers in the same ZIP code as Rhb Laboratories Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Vibra Of Southeastern Michigan, LLC | MI | Clinical Medical Laboratory | $1.4M | $25.7M |
| Pcor LLC | MI | Optometrist | $0 | $25.4M |
| Children's Dental Specialists PLLC | MI | Pediatric Dentistry | $0 | $9.8M |
| National Seating & Mobility Inc | MI | Durable Medical Equipment & Medical Supplies | $0 | $8M |
| Laboratory Corporation Of America | MI | Clinical Medical Laboratory | $1.8M | $3M |
| Alliance Mobile Health Inc | MI | Ambulance | $1.1M | $3.6M |
| Eye Surgery Center Of Michigan LLC | MI | Ambulatory Surgical Clinic/Center | $1.7M | $163.2K |
| Total Lab Solutions LLC | MI | Clinical Medical Laboratory | $638.6K | $768.5K |
| Bernardo Rojas | MI | Internal Medicine Physician | $1.2M | $0 |
| Troy Sc Center LLC | MI | Ambulatory Surgical Clinic/Center | $421.1K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.